Called Covaxin outside the US, the vaccine is developed by Ocugen’s partner Bharat Biotech, along with ICMR –NIV. Credit: DTM / commons.wikimedia.org.

The US Food and Drug Administration (FDA) has lifted the clinical hold on Ocugen’s Investigational New Drug application (IND) to assess the Covid-19 vaccine candidate, BBV152.

Called Covaxin outside the US, it is a whole-virion inactivated Covid-19 investigational vaccine candidate.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Ocugen’s partner Bharat Biotech developed the vaccine in partnership with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).

The highly purified vaccine leverages the same vero cell manufacturing platform utilised in producing polio vaccines.

The latest move comes after the FDA placed a clinical hold on the IND application for the vaccine in November last year. 

Ocugen CEO, co-founder and board chairman Dr Shankar Musunuri said: “We are pleased to be able to move our clinical programme for Covaxin forward, which we hope will bring us closer to offering an alternative Covid-19 vaccine. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We firmly believe that managing this pandemic requires more than one approach to vaccines, so we are heartened to be able to continue developing our vaccine candidate.”

At present, Covaxin obtained emergency use authorizations (EUA) in 20 countries with EUA applications pending in more than 60 countries. 

In November last year, the World Health Organization (WHO) has granted Emergency Use Listing (EUL) to Covaxin for usage in people of the age 18 years and above.

Earlier this year, Ocugen reported data from a study where sera collected from individuals who received a booster vaccine dose six months following the initial two-dose regimen showed to neutralise the Omicron and Delta variants of the SARS-CoV-2 virus.

Furthermore, prior studies showed the vaccine’s neutralising potential against various other variants, including Alpha, Beta and Delta.